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ORIGINAL ARTICLE
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Abstract
Genetic background signiﬁcantly affects phenotype in multiple mouse models of human diseases, including muscular
dystrophy. This phenotypic variability is partly attributed to genetic modiﬁers that regulate the disease process. Studies have
demonstrated that introduction of the γ-sarcoglycan-null allele onto the DBA/2J background confers a more severe muscular
dystrophy phenotype than the original strain, demonstrating the presence of genetic modiﬁer loci in the DBA/2J background. To
characterize the phenotype of dystrophin deﬁciency on the DBA/2J background, we created and phenotyped DBA/2J-congenic
Dmdmdx mice (D2-mdx) and compared them with the original, C57BL/10ScSn-Dmdmdx (B10-mdx) model. These strains were
compared with their respective control strains at multiple time points between 6 and 52 weeks of age. Skeletal and cardiac
muscle function, inﬂammation, regeneration, histology and biochemistry were characterized. We found that D2-mdx mice
showed signiﬁcantly reduced skeletal muscle function as early as 7 weeks and reduced cardiac function by 28 weeks, suggesting
that the disease phenotype is more severe than in B10-mdx mice. In addition, D2-mdx mice showed fewer central myonuclei
and increased calciﬁcations in the skeletal muscle, heart and diaphragm at 7 weeks, suggesting that their pathology is different
from the B10-mdx mice. The new D2-mdx model with an earlier onset and more pronounced dystrophy phenotype may be
useful for evaluating therapies that target cardiac and skeletal muscle function in dystrophin-deﬁcient mice. Our data align the
D2-mdx with Duchenne muscular dystrophy patients with the LTBP4 genetic modiﬁer, making it one of the few instances of
cross-species genetic modiﬁers of monogenic traits.

Introduction
Genetic backgrounds affect disease phenotype in both mice and
humans, for example in models for amyotrophic lateral sclerosis

(ALS) or muscular dystrophy and patients with mutations causing ALS (1–4). A stop codon mutation within exon 23 of the
mouse dystrophin gene (Dmd) on the X chromosome results in
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age and compared them with the standard B10-mdx and the two
respective background control strains (DBA/2 and C57BL/10),
thereby extending the age range studied by Fukada et al. (10).
Some of the parameters were assessed and reproduced in two
different laboratories [the Children’s National Medical Center
(CNMC) and The Jackson Laboratory] in independent cohorts of
mice. We also analyzed muscular dystrophy features that were
not documented in the ﬁrst report, namely the cardiomyopathy,
mRNA expression proﬁles of the skeletal muscles and inﬂammation. We found that D2-mdx mice showed signiﬁcantly reduced
cardiac and skeletal muscle function and increased inﬂammation, suggesting that genetic background signiﬁcantly affects
the disease phenotype of dystrophic mice.

Results
Body weight
The body weights for mice were measured at 7, 28 and 52 weeks
of age (Supplementary Material, Table S1). We compared body
weights recorded at the 28-week time point at both the CNMC
(Fig. 1A) and The Jackson Laboratory (Fig. 1B). We found that
B10-mdx mice were generally bigger than the B10 controls, whereas the D2-mdx mice were signiﬁcantly smaller than the DBA/2
control mice. The two wild-type strains (B10 and D2) were not
signiﬁcantly different from each other at this age, whereas
D2-mdx mice were signiﬁcantly smaller than the B10-mdx mice.
The differences in the body weights between the mdx and
wild-type strains were consistent between the two laboratories
(Fig. 1A and B).

Tissue weights
We examined the weights of the gastrocnemius, tibialis anterior
(TA) and quadriceps muscles and the heart and spleen tissues in
all strains (Supplementary Material, Table S1). We found that the
muscle weights of the two control strains were the most similar.
For all three muscles, the B10-mdx mice showed an increase in
muscle mass. In contrast, D2-mdx mice showed a loss of muscle
mass in all three muscles at all time points when compared with
the D2 mice. The muscle/body weight ratios for many muscles
were lower in the D2-mdx than in D2 mice from the 28th week
on, suggesting a muscle atrophy, whereas the muscle/body
weight ratios in B10-mdx were higher than in B10 mice, reﬂecting

Figure 1. Loss of body mass in the D2-mdx strain was observed independently.
Body mass was recorded for all four strains independently at both CNMC
(A) and The Jackson Laboratory (B). Results for body weights taken at 28 weeks
are shown. Signiﬁcant differences within the same genetic background are
marked with the asterisk symbol. Signiﬁcant differences between the two mdx
strains are marked with the hash symbol. B10-mdx mice were heavier than their
B10 wild-type controls as expected. In contrast, the D2-mdx strain was
consistently smaller than D2 control. n = 6 mice per group, average ± SEM).
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the absence of dystrophin (5,6). The skeletal muscles in these
mice on a C57BL/10 (B10) background (C57BL/10-mdx mice)
undergo cycles of degeneration and regeneration, along with inﬁltration of immune cells and elevated levels of serum creatine
kinase (CK). As compared with B10 wild-type control mice, both
male and female mdx mice have reduced life spans (7). These
mice do not typically show signiﬁcant fatty replacement or ﬁbrosis
in the skeletal muscle. However, unlike the skeletal muscle, the
diaphragm in dystrophin-deﬁcient mice undergoes extensive progressive degeneration, mineralization and regeneration, followed
by ﬁbrosis and a loss of myoﬁbers (8). Despite the milder phenotype in skeletal muscle, these mice are routinely used in preclinical evaluations because they are genetic and biochemical homologs
of human Duchenne muscular dystrophy (DMD). In fact, the B10mdx mouse is the most widely used mouse model for DMD.
Genetic mapping studies performed in Dr. Elizabeth McNally’s
group have shown that the introduction of the mouse sarcoglycan
gamma (Sgcg)-null allele onto the DBA/2J genetic background confers a more severe muscular dystrophy phenotype than that in the
129T2/SvEmsJ strain, demonstrating that genetic modiﬁer loci in
the DBA/2J background affect the disease phenotype of Sgcg-null
mice. Furthermore, this group identiﬁed one of the genetic loci
responsible for the difference in the severity of the phenotypes
of the Sgcg-null mutation in 129T2/SvEmsJ and DBA/2. They
found that a polymorphism in the coding region of the latent
TGF-β-binding protein 4 gene (Ltbp4) results in a 12-amino acid
deletion in LTBP4 in the DBA/2 mice. This deletion is associated
with increased proteolysis, SMAD signaling and ﬁbrosis, and the
proposed mechanism is that Ltbp4, which down-regulates TGF-β
signaling in its full-length form, is less active in DBA/2 mice,
thus allowing a stronger inﬂammation response to the lossof-function of Sgcg; this, in turn, worsens the associated muscle
pathology and modiﬁes the outcome of the muscular dystrophy
in this model (9). Beside a reduced TGF-β signaling, DBA/2 mice
also present with a lower self-renewal efﬁciency of the satellite
cells than that of C57BL/6 mice. Based on this ﬁnding, Fukada
et al. generated a DBA/2-mdx strain by crossing DBA/2 and
C57BL/10-mdx. They found that the hind limb muscles of DBA/2mdx mice exhibited increased weakness, lower muscle weight,
fewer myoﬁbers and increased fat and ﬁbrosis when compared
with B10-mdx mice, suggesting that the satellite cells’ self-renewal
ability may be one of reasons for the differences in pathology
between these mouse strains (10).
The human LTBP4 locus has been similarly shown to be a genetic modiﬁer of disease severity in DMD patients. A four-locus
haplotype in the LTBP4 gene was shown to be associated with
age at loss of ambulation (11). Patients with the homozygous
IAAM amino acid haplotype showed approximately a 2-year
later loss of ambulation compared with other genotypes. This
ﬁnding was validated in two additional DMD cohorts (12,13).
These ﬁndings suggest that studies of the mdx mutation modiﬁed by LTBP4 polymorphisms (DBA background) in mice are highly relevant to the human DMD disease, and likely predictive of
human pathophysiology.
To further investigate the effect of genetic background on the
dystrophic phenotype, we have re-created a DBA/2J-congenic
DMD mdx (D2-mdx strain) mouse model with a better deﬁned
genetic make-up (see Materials and Methods). Contrary to the
approach previously used to make the ﬁrst congenic mice, we
used an SNP-panel-assisted breeding strategy that allowed us
to exclude most of the original C57BL/10J genome from the new
D2.B10 mdx congenic (see Materials and Methods). We have
systematically assessed the functional, histological, biochemical
and molecular phenotype of these mice at 7, 28 and 52 weeks of
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the well-documented muscle hypertrophy of this model. We also
found that the mass of the heart differed signiﬁcantly between
the two control strains. The mass of the heart did not differ between strains at 7 weeks of age, but with age, the D2 hearts became signiﬁcantly larger than the B10 hearts. This increase in
cardiac mass was mirrored in the D2-mdx mice, whose hearts
were similar in size to those of the D2 strain. However, the B10mdx mice were also observed to have enlarged hearts, relative
to the BL10 controls, although this enlargement was signiﬁcant
only at the last time point.

shifted in opposite directions by the mdx mutation, depending
on the background strain. B10-mdx mice were found to have
fewer normal-sized ﬁbers (375–1500 m2) and a greater proportion
of hypertrophic ﬁbers (>1500 m2) (Fig. 2B). This observation is
consistent with prior ﬁndings of hypertrophy in this strain (14).
In contrast, the D2-mdx mice were found to have relatively few
hypertrophic ﬁbers alongside a large number of small ﬁbers. Speciﬁcally, the average ﬁber diameter was reduced to 375 m2, from
the average of 750 m2 seen in control DBA/2 mice. These results
are consistent with our ﬁndings regarding changes in muscle
mass and muscle/body weight ratios between the two strains.

Fiber diameter measurement
Creatine kinase enzyme activity
Serum CK enzyme activity was determined at 28 weeks of age by
both the CNMC (Fig. 3A) and The Jackson Laboratory (Fig. 3B). The
two control strains (B10 and D2) were found to have minimal
amounts of CK activity. Both mdx-mutant strains were observed
to have signiﬁcantly elevated levels of serum CK activity when

Figure 2. D2-mdx mice do not exhibit the hypertrophy that is seen in B10-mdx mice. The TA from each mouse was dissected at 12 weeks and preserved in 4% formalin prior to
staining for reticulin (A). Fiber area was then measured for each strain as shown in (B). The plot shows the ﬁber areas that were ranked by size, averaged and expressed as a
percentage of the total ﬁber sample for each strain: B10, B10-mdx, D2, D2-mdx. Statistical analysis was performed by the Kolmogorov–Smirnov (K–S) two-sample test; B10 versus
D2, P = 0.034; B10 versus B10-mdx, P = 0.018; D2 versus D2-mdx, P = 0.341; B10-mdx versus D2-mdx, P = 0.039. n = 4 (B10-mdx and D2-mdx), 6 (B10) and 8 (D2) mice per group.
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To determine the effect of genetic background on muscle ﬁber
diameter, we evaluated the average diameter of the muscle ﬁbers
in the TA muscle. Cross sections of the ﬁxed TA muscle were
stained for reticulin in order to clearly mark muscle ﬁber perimeters. Representative images of reticulin staining are shown
in Figure 2A. We found that the average ﬁber diameters were
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showed a lower EDL mass than did the control D2 mice at 28
and 52 weeks of age (Fig. 6A).
We then evaluated the maximal force and speciﬁc force production of the EDL muscles but did not detect any signiﬁcant differences in either the maximal or speciﬁc force between the two
wild-type control strains at any time point. The maximal force
shown by the EDL muscles of the BL10-mdx mice was similar to
that of the BL10 controls at all time points (Fig. 6B). In contrast,
the speciﬁc force signiﬁcantly decreased at all time points in
the BL10-mdx mice when compared with the BL10 controls
(Fig. 6C). Unlike the BL10-mdx mice, the D2-mdx mice showed a
signiﬁcant reduction in both maximal and speciﬁc force at all
three time points tested (Fig. 6B and C).
Figure 3. Both mdx strains show similar serum CK proﬁles. Levels of CK enzyme
activity in the serum from all four strains were measured at 28 weeks at CNMC
between the two labs. Serum CK levels for D2-mdx mice were signiﬁcantly
higher than normal baseline levels but on average were lower than the levels
seen in B10-mdx mice. n = 8 (B10.mdx), 11 (D2.mdx) and 12 (B10 and D2 controls)
mice per group, average ± SEM.

compared with age-matched controls. D2-mdx mice showed
relatively lower serum CK levels than did the B10-mdx mice at
24 weeks of age. The serum CK data were consistent between
the two laboratories.

Evans blue dye uptake
Damage to muscle ﬁbers can also be measured by quantifying the
uptake of Evans blue dye (EBD) by the muscle tissue. Incorporated
EBD can either be visualized via ﬂuoroscopy in ﬁxed tissues
(Fig. 4A–D) or quantiﬁed in muscle lysates via spectroscopy
(Fig. 4E). The quantiﬁcation of EBD retained within these tissues
conﬁrmed that the two mdx strains had signiﬁcant uptake when
compared with their respective controls. However, the D2-mdx
mice were found to have a signiﬁcantly higher uptake of EBD
than did the B10-mdx mice.

Echocardiography and cardiac function
The assessment of heart function was carried out using echocardiography on live, sedated mice. We found that the ejection fraction (EF) and shortening fractions (SF) were signiﬁcantly higher at
7 weeks of age in the wild-type D2 mice than in the wild-type
BL10 mice; heart weights were also signiﬁcantly different between the two genotypes. However, cardiac output normalized
to heart rate did not change when comparing wild-type D2 and
BL10 mice, indicating that the increase in heart mass is not
pathologically related to heart failure, because EF is maintained
or increased in wild-type D2 mice (Supplementary Material,
Table S1). Additionally, these differences were lost at 28 and 52
weeks of age. The D2-mdx mice showed a signiﬁcantly lower EF
and SF than did the control D2 strain, whereas the EF and SF values for the BL10-mdx and BL10 mice were similar at 28 weeks of
age (Fig. 7 A and B). By 52 weeks of age, both strains showed signiﬁcant deﬁcits in EF and SF when compared with their respective wild-type strains. We also found a signiﬁcant drop in stroke
volume (Supplementary Material, Fig. S2A), and cardiac output
(Supplementary Material, Fig. S2B) in both strains when compared with their wild-type controls.

Histological (H&E) evaluation of muscle tissues
Grip strength
The grip-strength measure (GSM) for all four mouse strains was
performed at both the CNMC and the Jackson Laboratory. At
CNMC, GSM was measured at 28 and 52 weeks of age in the forelimbs and hindlimbs, and at The Jackson laboratory in the forelimbs at 6, 12 and 24 weeks of age (Supplementary Material,
Fig. S1). Because of the differences in the body weights of the
different strains, the forelimb and hindlimb maximal force (kgf )
data were normalized to the body weight of the animal and
are presented as normalized grip force (kgf/kg). There was an
overall decline in grip strength in all strains by 52 weeks of age
(Supplementary Material, Fig. S1). mdx mice on both backgrounds
showed signiﬁcantly lower normalized grip strength than did
their respective control mouse strains in both laboratories at
the 24- or 28-week time points (Fig. 5A and B). The normalized
GSM data for the hindlimbs collected at the CNMC were consistent with the forelimb data collected at both laboratories.

In vitro extensor digitorum longus force contraction
The weights of the extensor digitorum longus (EDL) muscles
showed that the D2 mice had signiﬁcantly smaller EDL muscles
than did the BL10 mice at 7 weeks of age, and these differences
were reduced at the 28-week and 52-week time points. B10-mdx
mice showed signiﬁcantly more muscle mass than did control
BL10 mice at 28 and 52 weeks of age, whereas D2-mdx mice

We examined the diaphragm, quadriceps and heart muscles for
muscle damage at 7, 28 and 52 weeks of age. Representative
images for the diaphragm (Fig. 8A), heart (Fig. 8B) and quadriceps
(Supplementary Material, Fig. S3) are shown for all four strains
at all three time points. The histologic appearance of all three
tissues was normal for the control BL10 and D2 strains at all
time points. At 7 weeks, both mdx strains showed lesions exhibiting muscle degeneration, regeneration and mononuclear inﬁltrating cells within the quadriceps and diaphragm. In addition,
the D2-mdx mice, but not the B10-mdx mice, showed signiﬁcant
calciﬁcation in all tissues. We also observed that the D2-mdx
mice showed signs of inﬂammation within the cardiac tissue
at 7 weeks of age, whereas the B10-mdx mice showed normal
cardiac histology at that age.
To quantify the calciﬁed deposits, we performed microCT
scanning (Supplementary Material, Fig. S4A–C) and found that
calciﬁed deposits were distributed throughout the muscle tissue
in the quadriceps, diaphragm and in the epicardium of the heart
tissue. Overall, a signiﬁcant increase in tissue density as early as
at 7 weeks of age was seen only in the D2-mdx mice (Supplementary Material, Fig. S4D–F).

Optical imaging to monitor muscle inﬂammation
We have previously demonstrated that optical imaging of
Cathepsin B (CTSB) activity in live mice using cathepsin caged
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(A) and at 24 weeks at The Jackson Laboratory (B). The results were consistent
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and D2-mdx (C, D) muscles show retained EBD in red and positive myh3 staining in green. EBD absorbance from gastrocnemius lysates was quantiﬁed by spectroscopy and
normalized to total protein concentration in grams. (E). n = 8 (B10.mdx), 9 (D2.mdx) and 12 (B10 and D2 controls) mice per group, average ± SEM.

near-infrared imaging is an ideal method to sensitively monitor
inﬂammation and regeneration in dystrophic skeletal muscle
(15). We evaluated cathepsin activity in all mouse strains at
7 and 52 weeks of age (Supplementary Material, Fig. S5) and
found that cathepsin activity in the forelimb was similar between
wild-type strains at both ages whereas hind limb cathepsin activity was higher in D2 mice at 7 weeks and decreased signiﬁcantly
at 52 weeks in comparison with BL10 mice. Both BL10.mdx and
D2-mdx mice show highly signiﬁcant elevation of cathepsin
activity in both fore and hindlimbs at 7 weeks in comparison
with wild-type control strains. D2-mdx but not BL10-mdx mice
show signiﬁcantly increased cathepsin activity at 52 weeks of
age in comparison with their respective controls. The differences
in cathepsin activity between the strains are less marked at
52 weeks of age (Fig. 9A and B).

QRT–PCR of inﬂammatory genes
To determine whether the components of the inﬂammatory
process differed between the B10-mdx and D2-mdx mice, we
analyzed the relative gene expression of 14 different inﬂammation-related transcripts in all four strains of mice. This QRT–
PCR procedure was performed at CNMC using mRNA isolated
from the TA muscle taken at the 7-week and 52-week time points.
Similar QRT–PCR analyses were carried out at the Jackson Laboratory at the 12-week time point. In general, the results from both
labs conﬁrmed that there were signiﬁcant differences between
the two mdx strains. Figure 10 shows the change in relative
expression over time for a select few of the assayed genes. A complete table of the QRT–PCR results from both laboratories is provided in Supplementary Material, Table S2. Pro-inﬂammatory
cytokines such as TNF-alpha were consistently elevated at both
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Figure 4. D2-mdx show increased levels of EBD uptake compared with B10-mdx. In order to quantify muscle ﬁber damage, the gastrocnemius and TA muscle were dissected
from all four strains of mice at 8 weeks of age. All mice were injected with EBD 24 h prior to being sacriﬁced. Representative ﬂuorescent cross sections from B10-mdx (A, B)
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in their drinking water. BrdU is a nucleotide analog that is incorporated into newly synthesized DNA and can later be visualized
by immunohistochemical staining. Representative images of
BrdU-labeled muscles from B10-mdx and D2-mdx TA muscles are
shown in Figure 11C and D. A comparison between the two mdx
strains revealed foci of regeneration containing similar total numbers of BrdU-positive myonuclei within muscle ﬁbers of the TA
(Fig. 11F), but in the D2-mdx mice, these were predominantly
located in a juxtasarcolemmal position whereas in the B10-mdx
muscles they were predominantly centrally located (Fig. 11G).

Central nuclei and BrdU labeling

Myosin heavy chain expression

Central nucleated ﬁbers are markers of muscle regeneration.
Using H&E-stained sections, we quantiﬁed the percentage of centrally nucleated ﬁbers in cross sections of B10-mdx and D2-mdx
skeletal muscle (Fig. 11A and B). Both mdx strains showed signiﬁcantly higher numbers of centrally nucleated ﬁbers than in their
respective wild-type strains, but the D2-mdx mice showed signiﬁcantly fewer centrally nucleated ﬁbers than did the B10-mdx mice
(Fig. 11E).
To evaluate whether the turnover of myonuclei differs between
the two mdx mouse strains, we added bromodeoxyuridine (BrdU)

Muscle ﬁbers express various homologs of the myosin heavy
chain protein at various stages of development or repair. Embryonic and neonatal myosin genes (Myh3 and Myh8, respectively)
are markers for muscle ﬁber regeneration when they are expressed in adult muscles (16). Differential myosin expression
can also be used to distinguish various muscle ﬁber types as
fast type IIA (Myh2), fast type IIB (Myh4) or slow type (Myh7).
Slow muscle ﬁbers express higher levels of utrophin and have
an increased mitochondrial respiration, both of which have
been proposed as mitigating factors in DMD (17,18). Therefore,
we tested the hypothesis that the severe pathology seen in the
D2-mdx mice could be explained by a lack of either regenerating
or slow-type muscle ﬁbers.
Myosin expression was quantiﬁed at the RNA level in all four
mouse strains at the 8-week time point (Fig. 11H). As expected,
the two healthy background strains showed low levels of expression of Myh3 and Myh8 (markers for regeneration) when compared with the mdx-mutant strains. The signiﬁcantly elevated
(P < 0.001) levels of Myh3 and Myh8 seen in B10-mdx mice are consistent with prior reports (19), and the D2-mdx strain had similarly high levels of Myh3 and Myh8 expression. Both the healthy
DBA/2 and mutant D2-mdx strains were observed to have signiﬁcantly higher (P < 0.01) basal levels of Myh7 expression than did
the control B10 and mutant B10-mdx strains. There were no differences in Myh4 and Myh2 expression for either strain.

Figure 5. Loss of grip strength in the D2-mdx strain was observed independently.
Forelimb grip strength was recorded for all four strains independently at both
CNMC (A) and The Jackson Laboratory (B). Results for grip strength taken at 28
weeks are shown. All grip-strength measurements are normalized to the
individual animal’s body weight. Both mdx strains were signiﬁcantly weaker
than their wild-type controls. The same trends in forelimb grip strength were
also reproducible between labs.

Myoﬁber branching and myonuclear domain
Muscle ﬁbers were isolated from the EDL of D2 and D2-mdx male
mice at 12 weeks of age in order to compare ﬁber size, extent of

Figure 6. D2-mdx mice experience signiﬁcant muscle weakness at all ages. Force contraction analysis was performed on the freshly dissected EDL muscle of all strains at
7, 28 and 52 weeks at CNMC. Data for the mass of the EDL muscle (A), maximum force generation (B) and speciﬁc force generation (C) are shown. The B10-mdx mice showed
the expected deﬁcit in speciﬁc force generation starting at 28 weeks. However, D2-mdx mice displayed signiﬁcant muscle weakness both in terms of maximum and speciﬁc
force generation beginning at the earliest time point. The mass EDL of the D2-mdx mouse was also signiﬁcantly lower than its wild-type control.
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time points in the mdx strains when compared with their wildtype controls, whereas other pro-inﬂammatory cytokines such
as IL-6 and IL-1-beta were increased at 52 weeks of age in both
mdx strains when compared with their controls (Fig. 10). These
two cytokines were signiﬁcantly higher in the D2-mdx mice
than in the B10-mdx mice. Some markers of macrophage migration (CCL2 and EMR1) were highly upregulated in both strains
early in the disease and showed a signiﬁcant decrease at a latter
age. Type 1 IFNb was expressed to a greater extent in the control
strains than in the mdx mouse strains.
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Figure 7. D2-mdx mice develop signs of cardiomyopathy earlier than B10-mdx
mice. Echocardiography was performed by CNMC at 7, 28 and 52 weeks (A, B)
for each mouse strain. The data analysis showed that the D2-mdx mice showed
detectable deﬁcits in the EF (A) and shortening fraction (B) starting at 28 weeks,
prior to the appearance of any cardiomyopathy in B10-mdx mice. The functional

branching and myonuclear domain. We calculated ﬁber size by
staining with phalloidin in order to quantify the amount of
F-actin per ﬁber in relation to the number of myonuclei (20).
D2-mdx were found to have slightly more nuclei per ﬁber and
decreased F-actin content indicative of a smaller ﬁber size—i.e.
D2-mdx ﬁbers are atrophic compared with D2 (Fig. 12 C, D, E).
Also, D2-mdx ﬁbers showed a high incidence of primary and complex branching, which was not observed in the D2 control ﬁbers
(Fig. 12A, B). D2-mdx ﬁbers contained an average of 290.5 ± 64.4
myonuclei, whereas D2 control ﬁbers contained 262.3 ± 38.6
(P < 0.001) (Fig. 12D). Calculation of the normalized ratio of
F-actin protein content per myonucleus in each ﬁber revealed
this variable to be signiﬁcantly lower in D2-mdx, than in D2-WT
ﬁbers (Fig. 12E); D2-mdx had a normalized ratio of 1.659 ± 0.766
whereas the ratio for D2 ﬁbers was 2.299 ± 0.473 (P < 0.001), indicating a 28% smaller myonuclear domain in D2-mdx than in D2
myoﬁbers.

Discussion
It is well known that the phenotype of a given single-gene mutation in mice is modulated by the genetic background of the inbred
mouse strain in which the mutation is maintained. This effect is
attributable to modiﬁer genes, which function in combination
with the causative gene. Developing congenic mouse strains
not only helps us to investigate the effect of genetic background
on phenotype but would also facilitate the development of
mouse models that more accurately mimic certain features of
human disease (21). The commonly used mdx mouse models
for DMD are on the C57BL/10ScSn background. In these mice,
the disease progression in skeletal muscle (with the exception
of the diaphragm) is mild when compared with the disease progression in humans. It has previously been shown that transfer of
the γ-sarcoglycan-null allele and the mdx mutation onto the DBA/
2J background confers a more severe muscular dystrophy phenotype (9,10). Therefore, we decided to generate congenic mice carrying the mdx 23 mutation on the DBA2/J background. In this
paper, we report that mdx mice on the DBA2/J genetic background
have more skeletal muscle damage and inﬂammation, as well as
an earlier onset of cardiac disease when compared with mdx mice
on the C57BL/10ScSn background.
Systematic phenotyping of these mice in two different laboratories has revealed consistent and reproducible data. We measured body weights at three ages and tissue weights at the end
of the study and found that the body weights did not differ
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deﬁcits in cardiac function were corroborated by histological results as shown in
Figure 8B.

signiﬁcantly between the two strains of wild-type mice, but the
two mdx mouse strains showed opposite phenotypes in terms
of body weight. The B10-mdx mice were generally heavier than
the B10 controls, suggesting that some degree of hypertrophy
had occurred in the mutant strain. BL10 and B10-mdx muscles
generally attained maximum size by 12 to 14 weeks, at which
point the B10-mdx muscle ﬁbers were up to 50% larger than
those of the B10 mice (22). Conversely, the D2-mdx mice were
much smaller than those of the control DBA2 strain, suggesting
an atrophic phenotype. Our observations are consistent with a
previous report that has shown a signiﬁcant difference in muscle
weight to body weight ratio between D2-mdx and control littermates (10). Our study also demonstrates that the decrease in
body weight is associated with signiﬁcant decreases in the
weights of the gastrocnemius, TA and quadriceps muscles. The
differences in muscle mass were also observed in the sarcoglycan-null mice with a DBA/2 background (10), suggesting that genetic background has an inﬂuence on body weight and muscle
mass. Evaluation of the muscle ﬁber diameter of TA muscles suggested that a signiﬁcantly higher number of smaller ﬁbers were
present in the D2-mdx mice; thus, the differences in muscle
mass are apparently also reﬂected at the level of the muscle
ﬁber diameters. A major caveat of the B10-mdx model is its
overt muscular hypertrophy, caused by a strong regenerative response of the skeletal muscle that masks a slow ﬁbrosis and loss
of force. Pseudo-hypertrophy in Duchenne patients is more the
consequence of the accumulation of ﬁbrotic tissue and fat, and
not of the enlargement of muscle ﬁbers; instead, muscle ﬁbers
are reduced in size in patient biopsies (23). The atrophy documented in the D2.mdx mice supports the notion that hypertrophy is absent and that muscles are affected in a way more
relevant to the human pathology.
We next evaluated whether any of the muscle injury markers
were signiﬁcantly different in the two mdx mouse strains, by
quantitating serum CK levels as well as EBD uptake by the skeletal muscle. We found signiﬁcantly increased serum CK levels
in both strains when compared with their respective control
strains. The serum CK levels were slightly lower in the D2-mdx
mice than in the B10-mdx mice, the likely consequence of the
D2.mdx mice being smaller in weight, and having decreased
muscle/body weight ratios compared with the B10.mdx, leading
to a relatively smaller muscle mass leaking CK enzymes in the
serum. CK values in wild-type controls were slightly lower in
the Jackson Laboratory measurements, which could be attributed
to the use of different methods to dose the enzymatic activity, or
more signiﬁcantly, to differences in the time of day when blood
was collected. On the other hand, EBD dye uptake was signiﬁcantly higher in the D2-mdx mice than in the B10-mdx mice, suggesting that an increased number of leaky necrotic muscle ﬁbers
were present in both mutant strains, particularly in the case of
the D2-mdx mice. These data seem to contradict previous ﬁndings that have shown fewer total necrotic ﬁbers in D2-mdx mice
(10). However, while we documented EBD uptake in 8-week-old
mice, the previous report studied 8-month-old mice. It is expected that, as they age, D2.mdx mice, whose pathology is
more severe at an earlier onset, will lose muscle ﬁbers to ﬁbrosis
and calciﬁcation earlier than B10.mdx mice; in consequence, EBD
uptake should be higher in young mice (8 weeks of age) but decreased in older ones (8 months).
To evaluate the effect of genetic background on muscle function, we performed grip-strength measurements and also measured the in vitro force contractions of the EDL muscle. We
found that forelimb grip strength was signiﬁcantly reduced in
both mdx mouse strains at 28 weeks of age. A previous study by
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formalin prior to H&E staining. Tissue histology was normal for the control C57Bl10 and DBA2 strains. The B10-mdx strain showed expected inﬂammation in the
diaphragm. The D2-mdx strain displayed inﬂammation and calciﬁcations (see indicated examples) in the diaphragm at 7 weeks of age. Calcium deposits were only
observed in the diaphragm of D2-mdx mice. (B) D2-mdx mice show signs of cardiomyopathy at 7 weeks of age. The heart from each mouse was dissected at 7, 28 and
52 weeks and preserved in 4% formalin prior to H&E staining. Tissue histology was normal for the control C57Bl10 and DBA2 strains. All images show transverse
sections of the left ventricle wall. The B10-mdx did not show signs of cardiomyopathy until 28 weeks. The D2-mdx strain displayed inﬂammation and calciﬁcations
(see indicated examples) in the heart starting at 7 weeks of age. Calcium deposits were only observed in the D2-mdx mice.

Fukada et al., 2010 reported differences in grip strength between
D2-mdx and their congenic controls, but not between B10-mdx
and B10 control mice (10). It is pertinent to note that our gripstrength assessments were done in two independent groups of
mice by two different laboratories. As grip strength is subjected
to an animal’s volition, we also performed in vitro force measures
on isolated EDL muscles. The EDL muscle mass of D2-mdx mice
was, on average, much smaller than that of the B10-mdx mice;

the maximal force generated by the B10-mdx mice was equal to
that of both wild-type strains. Thus, the maximal force data obtained for both the BL10 and B10-mdx mice were consistent
with previous data reported in the literature (24). In contrast,
the speciﬁc force in both mdx strains was much lower than that
of the respective control strains; however, the D2-mdx mice generated a signiﬁcantly lower force than did the B10-mdx mice, suggesting that the muscle damage is more severe in the D2-mdx
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Figure 8. (A) Both mdx strains show inﬂammation in the diaphragm at all ages. The diaphragm from each mouse was dissected at 7, 28 and 52 weeks and preserved in 4%
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Figure 9. In vivo optical imaging conﬁrms increased cathepsin activity and
inﬂammation in mdx strains. The cathepsin-mediated cleavage of the ProSense
680 dye serves as a quantiﬁable marker for inﬂammation in vivo. Sedated mice
were imaged at 7 weeks and 52 weeks of age at CNMC. Cathepsin activity was
measured in the fore limbs (A) and in the hind limbs (B). Cathepsin activity was
signiﬁcantly higher in both mdx strains at 7 weeks of age when compared with
their respective healthy control strains.

macrophages (Lgals3 and Mpeg1) in the muscle of the mdx mice,
and this increase was more pronounced in the D2 background.
These data are also consistent with our previous study in which
we found stage-speciﬁc remodeling of human dystrophin-deﬁcient
muscle, with inﬂammatory pathways predominating in the early
stages and acute activation of TGF-β and failure of metabolic pathways, later in the disease (26). We also found that the early increase
and gradual drop in inﬂammation is reﬂected in the pro-inﬂammatory cytokine expression in skeletal muscle (27). Cytokines are differentially expressed in the wild-type strains (both backgrounds).
Furthermore, it is known that the DBA/2 strain has an in-frame
deletion within the LTBP4 gene that confers a severe disease
phenotype, and it has been proposed that its pathogenic effects
are mediated by excessive TGF-β signaling. Intriguingly, a polymorphism in LTBP4 has also been implicated in the pathogenesis
of DMD (11).
The self-renewal efﬁciency of satellite cells after muscle injury in the DBA/2 mouse strain has been shown to be lower
than that of C57BL/6 mice (10). Therefore, we counted the percentage of centrally nucleated ﬁbers (%CNF) and measured
BrdU uptake, and myosin heavy chain subtypes in muscle of
our four mouse strains. We found, as expected, that the %CNF
and of BrdU-positive central nuclei were signiﬁcantly lower in
the D2-mdx than in the B10-mdx and, intriguingly, that the total
frequency of myonuclei labeled with BrdU was similar between
the two strains. The difference is made up by a higher proportion
of BrdU-labeled myonuclei located peripherally in myoﬁbers of
D2-mdx mice. Our protocol is designed to identify myonuclei
formed from myogenic cells that had incorporated BrdU in Sphase during the 3-day period beginning 1 week before autopsy.
Because we cannot immunostain for Pax7 in the context of the
acid treatment entailed by the BrdU staining protocol, we cannot
formally rule out the possibility that the peripherally located
BrdU-positive nuclei included satellite cells, but, if so, they
would be far more numerous than normal satellite cell populations. However, we can still use these data as an index of myogenic activity over this period and conclude that the intensity

Figure 10. D2-mdx mice display signiﬁcant differences in inﬂammatory gene expression. We isolated mRNA from frozen TA muscle tissue from 6-week and 52-week-old
animals to examine inﬂammatory gene expression via QRT–PCR. A selection of signiﬁcantly altered genes is shown in A–F. C57Bl10 mice at 52 weeks were used as a
baseline for all calculations of changes in relative gene expression. Both D2-mdx and B10-mdx mice showed the same trends in the expression over time for both
soluble cytokines (A–E) and macrophage surface markers (F). Note that the changes in expression in D2-mdx mice are greater in magnitude than those in the B10-mdx mice.
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mice. Interestingly, the speciﬁc force deﬁcit stayed relatively
constant and did not change with age in either mdx mouse strain.
This force deﬁcit was consistent with our histological ﬁndings of
a more pronounced muscle pathology in D2-mdx than in B10-mdx
mice.
As muscle inﬂammation is a major component of the disease
pathogenesis in dystrophin deﬁciency, we previously developed
a method for detecting inﬂammation in live animals by using
optical imaging of cathepsin B (CTSB) activity. This sensitive
method for monitoring inﬂammation uses a caged near-infrared
CTSB substrate, ProSense 680 (15). Using this method, we have
now demonstrated that the CTSB activity is higher in both mdx
strains at 7 weeks of age and decreases signiﬁcantly by 52
weeks of age, suggesting that inﬂammation plays an important
role early in the disease process in both of these mouse models.
This trend in cathepsin activity is likely related to the inﬁltration
of macrophages (a major source of cathepsin release) (25). Indeed, we measured a very strong increase in mRNA markers of
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heavy chain subunits, markers of regeneration. Central nuclei are used as markers for successful muscle ﬁber regeneration. The TA of BrdU-treated animals and prepared
for either H&E staining (A, B) or immunoﬂuorescence (C, D). Frozen sections were stained with anti-BrdU (white colored) and anti-laminin (light gray colored). The
proportion of centrally nucleated ﬁbers versus healthy uninjured ﬁbers was quantiﬁed for all four strains (E). Both mdx-mutant strains possessed signiﬁcantly more
central nucleated ﬁbers than their respective controls. The quantiﬁcation of BrdU-labeled nuclei showed that both strains had similar numbers of newly proliferated
cells (F) but that the D2-mdx mice possessed fewer BrdU-positive central nuclei than B10-mdx mice. Myosin gene expression in the TA was determined for all four
strains by QRT–PCR (H). The D2-mdx mice suffered from greater muscle ﬁber damage than B10-mdx mice as measured by EBD uptake. However, levels of embryonic
myosin (myh3) or perinatal myosin (myh8) were comparable between the two mdx strains. E: n = 4 (B10.mdx and D2.mdx), 6 (B10) and 8 (D2) mice per group,
average ± SEM, H: n = 3 mice per group, average ± SEM.

of regeneration is similar in the two mdx strains but that myoblast
fusion differs in some way between the two. Counts on isolated
myoﬁbers of 3-month-old mice showed similar numbers of myonuclei per ﬁber in D2 mice to those previously reported in B10
mice (22). However, whereas B10-mdx mice contained more
than twice as many myonuclei as the B10, the D2-mdx myoﬁbers
contained only slightly elevated numbers of nuclei (22). In both
mdx strains, however, the nuclear/sarcoplasmic ratio was markedly lower than in the wild-type strains, suggesting that this
may be a common feature of the mdx phenotype. These differences were not reﬂected at the level of the embryonic (Myh3)

and neonatal (Myh8) myosin transcripts expression, which are
markers of regeneration. We also tested the hypothesis that D2.
mdx has a more severe phenotype because of a lower percentage
in slow ﬁbers (that are more resistant to the disease); this was
refuted by the experiments and our conclusion is that the origin
of the more severe phenotype is to be sought elsewhere.
Unlike the B10-mdx mice, we found that the D2-mdx mice
showed exacerbated calciﬁcation in their skeletal muscle, diaphragm and heart tissue; this may be strain-speciﬁc, because
dystrophic cardiac calciﬁcations are often found in DBA/2 mice,
reportedly in association with low plasma magnesium levels
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Figure 11. D2-mdx mice show a deﬁciency of central nuclei despite nuclear proliferation in damaged tissues and similar expression of embryonic and neonatal myosin
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mice; total of 102 ﬁbers) and D2-mdx (n = 3 mice; total of 108 ﬁbers). (C). Myonuclei per myoﬁber quantiﬁed for D2 and D2-mdx showing signiﬁcant increase in average
number of nuclei per ﬁber. Plots show the mean with S.D. (T-test, ***P < 0.001) (D). Normalized F-actin per myonuclei quantiﬁed showing a decrease in myonuclear
domain for D2-mdx compared with controls. Plots show the mean with S.D. (T-test, ***P < 0.001) (E).

(28). Fibrosis, an important feature of muscular dystrophy, has
not been measured in this study, but ongoing experiments will
address whether ﬁbrosis is more important in D2-mdx than in
B10-mdx—as can be hypothesized based on the increased signaling of the proﬁbrotic TGF-beta pathway previously documented
in the D2 background.
We have previously shown that heart dysfunction in B10-mdx
mice is prominent at 9–10 months of age and is associated with a
signiﬁcantly increased LV internal diameter (at the end of the
systole) and a decreased posterior wall thickness. This cardiomyopathy is associated with a 30% decrease in the shortening fraction
(29). Our current evaluations of cardiac function now reveal that
the D2-mdx mice show early cardiomyopathy by 28 weeks of age,
considerably earlier than their B10-mdx counterparts. These echocardiography results were also consistent with our histological
ﬁndings. Speciﬁcally, we observed cardiac tissue inﬂammation
and damage in D2-mdx mice as early as 7 weeks of age, and this
damage became progressively worse over time. In contrast, the
B10-mdx mice did not show any histological signs of cardiomyopathy until 28 weeks, and functional deﬁcits on echocardiography
were not seen until the testing at the 52-week time point.
Further exploration of the genetic and physiological differences between the two inbred strains of mice, C57BL10/J and
DBA/2J, which account for the differences in the phenotypes of
the same mdx mutation, is underway. The ﬁrst genetic modiﬁer

in the DBA/2J genome that has been identiﬁed, a partial lossof-function mutation in Ltbp4, has already been related to an
increased atrophy of the dystrophic muscles in this strain: mutant Ltbp4 fails to sequester TGF-β, resulting in an increased
signaling by this cytokine that is known to be pro-atrophic on
muscle ﬁbers. Moreover, TGF-β is also a known inhibitor of
the myogenic differentiation, i.e. of the fusion of myoblasts
into myotubes (30). The decreased regeneration potential of the
D2.mdx muscles could therefore be explained in part by the
increased TGF-β signaling. Whether other genetic determinants
explain the difference in myoblasts and/or satellite cells proliferation between C57BL/10 and DBA/2 remains to be elucidated.
Differential expression of inﬂammatory genes has also been
documented between DBA/2 and C57BL/6 (31) and could account
for the more severe inﬂammation observed in D2.mdx—a potent
driver of the dystrophic phenotype. These differences and others
likely to be discovered make the D2.mdx model more relevant to
human DMD.
In summary, our data suggest that D2-mdx mice have a severe
progressive muscle disease with early-onset cardiac deﬁcits.
The muscle hypertrophy response that is predominant in the
B10-mdx model and complicates the study of muscle wasting in
this strain is notably absent in the D2-mdx model. Thus, this
mouse model may be a particularly suitable model for evaluating
therapeutics for DMD.
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Figure 12. D2-mdx mice show increased myoﬁber branching and decrease in myonuclear domain. EDL myoﬁber isolation and phalloidin staining for DBA/2 and DBA/2-mdx
mice at 12 weeks ± 1 week of age (A, B). Both primary and complex ﬁber branch points were observed with high frequency in D2-mdx mice but not D2 (A,B). Total phalloidin
ﬂuorescence per myoﬁber, as an indicator of myoﬁber volume, plotted against the number of myonuclei per myoﬁber, displayed as individual data points for both D2 (n = 3
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Materials and Methods

Table 1. Primers used for genotyping

Animal husbandry

Primer name

Dye conjugate

Sequence

LTBP4 Forward
LTBP4 Reverse
MDX23 Forward
MDX23 Reverse
MDX23 Wild type
MDX23 Mutant

n/a
n/a
n/a
n/a
VIC
FAM

ctgggccacagcctgaac
aagcctttccccacagaaat
tgaggctctgcaaagttctttgaa
catctccttcacagtgtcactca
aagccattttgttgctct
aagccattttattgctct

actual data collection began. Force was measured according to
the amount of horizontal force that was required to break the
mouse’s grip from the mesh surface. Five successful hindlimb
and forelimb strength measurements were recorded within
2 min. The maximum values of each day over a 5-day period
were averaged and normalized to body weight and expressed as
KGF/kg unit.
CNMC behavioral activity testing
Voluntary activity in an open ﬁeld was measured using an openﬁeld Digi-Scan apparatus (Omnitech Electronics, Columbus, OH)
as described previously (27). All mice were acclimatized to the
scanning chamber 1 week prior to actual data collection. The
data were collected every 10 min over a 1-h period each day for
4 consecutive days. The results were calculated as mean ±
standard error for all recordings. The recorded quantitative measures of activity were horizontal activity, vertical activity, total
distance and rest time.
CNMC Rotarod testing
The latency-to-fall from the Rotarod apparatus was assessed as
described previously (27). In brief, mice were trained on the Rotarod (Ugo Basile, Italy) for 2 days before data collection was begun.
Each trial consisted of placing the mouse on the rod at 10 rpm for
60 s (stabilizing period), followed by acceleration from 10 rpm to
40 rpm. Each trial was done twice a day for 3 consecutive days,
with a minimum 2-h interval between the data collection
times. The latency-to-fall was recorded, and average values
were calculated from all six scores.

Genotyping
The DBA2 mouse strain has been reported to have a mutation in
the LTBP4 gene that may affect muscle function and regeneration
(9). Genotyping for this reported deletion mutation was carried
out by standard PCR, followed by gel electrophoresis. The product
size of the wild-type LTBP4 band is 273 bp, whereas the band for
the mutant is only 236 bp. The primers used to identify the LTBP4
status are listed in Table 1. Genotyping of the MDX exon 23 SNP
was performed via real-time allelic discrimination using custommade Taqman® ﬂuorescent-bound primers. SNP genotyping reactions were conducted using the Taqman® SNP Genotyping Master
Mix according to the manufacturer’s recommendations. The primers used to identify the MDX23 SNP are listed in Table 1.

Functional and behavioral activities
CNMC grip-strength test
Grip strength for both fore- and hindlimbs was assessed using a
grip-strength meter consisting of a horizontal forelimb mesh and
an angled hind limb mesh (Columbus Instruments, Columbus,
OH) according to a previously published protocol (27). The animals were acclimatized on fore- and hindlimb meshes for 3 consecutive days prior to data collection, and then for 90 s before

Jackson Laboratory grip-strength measurements
The strength exerted by the forelimbs of an animal in response to
a constant horizontal force was measured. The grip-strength
meter (Chatillon-Ametek Digital Force Gauge, DFIS 2, Columbus
Instruments) was positioned horizontally, with the triangular
metal transducer situated 10 cm above a foam platform. Each
mouse was raised toward the triangular transducer, and it instinctively grasped for the bar. Care was taken to ensure the
mouse was holding the grip transducer properly with, and only
with, both front paws. Once an appropriate grip was observed,
the animal was pulled horizontally from the bar. Peak force was
measured in kilogram for ﬁve consecutive trials per mouse. The
maximum force was retained for each animal. For the fatigue
quantiﬁcation, force at the ﬁfth trial was expressed as a percentage of the force at the ﬁrst trial. Forces were normalized to body
weight.
Jackson Laboratory behavioral activity measurements
Voluntary activity measurement consisted of recording 30 min of
the horizontal and vertical (rearing) activities in an open ﬁeld
(BiObserve, Germany) for each mouse. Mice were all tested in
the morning (9–11 am).
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Animals were housed at a density of up to ﬁve males or ﬁve
females per cage under speciﬁc pathogen-free conditions in
rooms with a 12-h light/12-h dark cycle at a temperature of
18–23°C and 40–60% humidity. At the CNMC, all mice were
handled according the local guidelines established by the Institutional Animal Care and Use Committee (IACUC) of the CNMC in
Washington, D.C., and all procedures were carried out under
the approved animal protocol. At The Jackson Laboratory, all
experiments were conducted in accordance with the protocols
described by the National Institutes of Health’s Guide for the
Care and Use of Animals and were approved by The Laboratory’s
institutional animal care and use committee. The wild-type
strains C57BL/10 (JAX Stock #000476 and #000665; B10) and
DBA/2 (JAX Stock #000671; D2) served as the genetic background
controls for the two mutant strains C57BL/10ScSn-Dmdmdx (JAX
Stock #001801; B10-mdx) and D2.B10-Dmdmdx/J (JAX Stock
#013141; D2-mdx), respectively. Control mice at CNMC were descended from stock #000476, and the equivalent controls at The
Jackson Laboratory were drawn from stock #000665. Only males
were used for this project.
The making of the B10.D2 congenic mouse at The Jackson
Laboratory was guided by the use of a 132-SNP panel genotyping
at each generation to insure that most of the C57BL10 genome
was removed from the D2.mdx mouse, an approach superior
to the repeated, but blind, crossing to the DBA/2 background
performed before. The panel is composed of an average of six
markers distributed across each chromosome. At each generation of a backcross to DBA/2J, mice with the lower number of
C57BL10-speciﬁc SNPs were selected to be crossed further to
inbred DBA/2J mice. At the ﬁfth generation, two founder males
we used to establish the B10.D2 colony, which were typed
homozygous for the DBA/2J alleles at all SNP loci but from
rs13483720 ( position 16,660,451 on GRCm38) to rs13483915 ( position 102,126,616 on GRCm38), SNPs ﬂanking the DMD gene ( position 82,948,870–85,206,141), where they were typed hemizygous
for the C57BL10 alleles.
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Force contractions on isolated skeletal muscle

Echocardiography
In order to assess the cardiac function of mice in vivo, we performed
echocardiography on sedated mice. Mice were ﬁrst anesthetized
with 5% isoﬂurane mixed with 100% oxygen at 1.0 l/min ﬂow and
then maintained under anesthesia with 1.5% isoﬂurane/oxygen
ﬂow. Ophthalmic ointment was placed on the eyes to prevent drying of the cornea while the mouse was anesthetized and tested.
After anesthetic induction, the animals were placed on a thermostatically controlled heated platform, where isoﬂurane anesthesia
was maintained by delivery through a close ﬁtting face-mask.
A heating lamp was also used to keep the heart rate and body temperature constant at physiological status during echocardiography.
During the examination, the animal’s heart rate was monitored
through the use of an electrocardiograph. The mouse’s heart rate
and body temperature were monitored continuously during
the scanning. Fur was removed from the ventral surface of the
mouse torso with clippers and Nair (Church & Dwight, Ewing,
NJ). Echocardiography was performed using Vevo770 ultrasound
machine (VisualSonics, Toronto, Canada). The 2-D (B-mode),
M-mode and Doppler images were acquired from a modiﬁed parasternal long axis view, parasternal short axis view, suprasternal
notch view and apical three-chamber view. The heart rate (BPM),
fractional shortening, EF, stroke volume and cardiac output were
obtained for cardiac function assessment using measurements

Optical imaging
Cathepsin enzyme activity is used as a marker for inﬂammation,
and this activity can be detected in vivo by detecting the cathepsin-mediated cleavage of certain dye molecules. Mice were prepared for optical imaging by administering an intraperitoneal
injection of 1.5 nmol of ProSense 680 (VisEn Medical), prepared
in a total volume of 150 µl, 24 h prior to imaging. On the day
of the imaging, mice were sedated using 1.5–2% isoﬂurane
and 100% oxygen before being placed inside the eXplore Optix
(GE Healthcare) scanning chamber. The ﬂoor of the scanning
chamber was continuously heated to maintain normal body temperature. Nair (Church & Dwight, Ewing, NJ) was used to remove
fur from the limbs prior to scanning. The scan plane was kept
consistent between the mice, at a height that was immediately
above the hindlimbs. The scanning area was limited to the
limbs. For scanning, a 670-nm excitation frequency was used
with a 1.0 mm resolution. Emissions were collected using a 700nm long-pass ﬁlter. The acquired photon intensity data were
automatically normalized by the Optiview 2.0 software to account for differences in scanning laser power and integration
times selected between mice. The measured cathepsin activity
was deﬁned as photon intensity ( photon counts/mm2).

MicroCT scan
The tissue density of formalin-ﬁxed tissues was determined by a
MicroCT scan. MicroCT analysis was performed on ﬁxed gastrocnemius, quadriceps, heart and diaphragm tissues using a SkyScan 1172 MicroCT (Bruker, Belgium). Imaging was performed
at a 40-kV source voltage, 250-µA source current, 295-ms exposure time and 0.4° rotation step, with a 0.5-mm aluminum ﬁlter.
The imaging resolution size was 9 µm. Three-dimensional reconstructions were performed with Skyscan NRecon and Dataviewer
software. For analysis, tissues were selected individually for a
polygonal region of interest within the whole tissue area. Tissue
density data were obtained from 3D analysis of the selected tissues using Skyscan CT-analyzer software.

Serum creatine kinase activity
At CNMC, blood was collected from mice via cardiac puncture immediately following sacriﬁce. Serum was separated from other
blood fractions by centrifugation and stored at −80°C without
EDTA or heparin. CK activity in the serum was measured using
the Creatine Kinase Reagent Set from Pointe Scientiﬁc, Inc. (Canton, MI) according to the manufacturer’s protocol. In brief, 25 µl of
serum was pipetted into a volume of pre-warmed detection
reagent in a 96-well plate and allowed to incubate for 2 min at
37°C. The absorbance of each well on the plate was then read
once per min for 5 min. The average change in absorbance was
then used to calculate the concentration of CK in U/l, where 1 U
was deﬁned as the amount of CK required to catalyze the conversion of one micromole of creatine phosphate in 1 min at 37°C. All
measurements were made on a BioRad xMark spectrophotometer at 340 nm at 37°C using a standard clear 96-well plate. At
The Jackson Laboratory, blood was collected by retro-orbital
sinus puncture into heparinized glass capillaries, immediately
after the last test. Serum was isolated by centrifugation for
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Force contraction experiments were conducted on the EDL muscle of the right hindlimb of each mouse. The mouse was anesthetized with an intraperitoneal injection containing ketamine
(100 mg/kg) and xylazine (10 mg/kg). The muscles were isolated,
and 6–0 silk sutures were tied securely to the distal and proximal
tendons. Each muscle was then carefully removed from the
mouse and placed vertically in a bath containing buffered mammalian Ringer’s solution (137 m NaCl, 24 m NaHCO3, 11 mm
glucose, 5 m KCl, 2 mm CaCl2, 1 mm MgSO4, 1 mm NaH2PO4
and 0.025 mm turbocurarine chloride) maintained at 25°C and
bubbled with 95% O2–5% CO2 to stabilize the pH at 7.4. The distal
tendon of the muscle was tied securely to the lever arm of a
servomotor/force transducer (model 305B, Aurora Scientiﬁc)
and the proximal tendon to a stationary post in the bath. After removal of the muscle, the mouse was euthanized by gassing with
CO2 according to IACUC guidelines. The muscle was stimulated
between two stainless steel plate electrodes. The voltage of single
0.2-ms square stimulation pulses was increased until supramaximal stimulation of the muscle was achieved, and the muscle
length was then adjusted to the length that resulted in maximal
twitch force (i.e., optimal length for force generation). With the
muscle held at optimal length, the force developed during trains
of stimulation pulses was recorded, and stimulation frequency
was increased till the maximal isometric tetanic force was
achieved. For the EDL muscle, 300-ms trains of pulses were
used, and a stimulus frequency of ∼220 Hz was typically needed
to achieve the maximum isometric force. The muscle length was
measured with calipers, and the optimal ﬁber length was calculated by multiplying the optimal muscle length by a constant of
0.45, an established ﬁber length/muscle length ratio for EDL muscle. The muscle mass was determined after removal of the muscle from the bath. The muscle-speciﬁc force, a measure of the
intrinsic force generation of the muscle, was calculated according
the following equation: speciﬁc force = maximal isometric force/
(muscle mass × (density of muscle tissue × ﬁber length)−1). The
muscle tissue density was 1.056 kg/l.

from the modiﬁed parasternal short axis view in the M-mode.
Qualitative and quantitative measurements were recorded using
Veto 770 ofﬂine workstation software, and post-imaging analysis
was performed using the VevoStrain analytic software.
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10 min at 19,000 rpm. Creatine kinase was measured with a Beckman Coulter AU Clinical Chemistry analyzer.

Histology
H&E staining
Freshly dissected tissues were prepared for histology by ﬁxing tissues with 0.4% neutral buffered formalin (Fisher Scientiﬁc) sealed
in glass scintillation vials (Fisher Scientiﬁc). Fixed tissues were
then sent to Hisotserv, Inc. (Germantown, MD) to be mounted
in parafﬁn wax, sectioned and stained with hematoxylin and
eosin (H&E). Tissue sections stained with H&E were imaged
using an Olympus BX51 microscope with attached Olympus
DP70 camera module.

Immunoﬂuorescent staining for utrophin and neonatal myosin
was performed on gastrocnemius, TA and diaphragm cryosections using the antibodies VP-U579 (Vector Laboratories) and
ab49457 (Abcam), respectively. An AlexaFluor® 488-goat antimouse IgG1 antibody (Life Technologies) was used as a secondary
antibody. Confocal (TCS SP5, Leica) images were acquired at 20×
magniﬁcation, and the number of positive ﬁbers per microscope
ﬁeld was counted. Counts from three ﬁelds were averaged for
each muscle.

(Sigma, E2129) was dissolved in PBS at 10 mg/ml. Each animal received an intraperitoneal injection at 5 µl/g body weight; 24 h
after the injection, the gastrocnemius muscles were harvested,
homogenized and incubated at 55°C in 1 ml formamide for 2 h.
The suspension was cleared by centrifugation at 6000g for
5 min, and spectrophotometric absorbance was measured at
620 nm on the cleared lysate. Protein concentration was determined by BCA assay (Pierce, catalog # 23225). Results were recorded as absorbance/microgram of tissue.

Myosin heavy chain identiﬁcation
For the myosin isoform quantiﬁcation, assays were performed for
the following: myosin 3 (embryonic) (PrimerBank ID 153792648c1),
myosin 8 (neonatal) (PrimerBank ID 28893527a1), myosin 7 (slow)
(PrimerBank ID 118131045c1), myosin 4 (fast IIB) (PrimerBank ID
67189166c1) and myosin 2 (fast IIA) (PrimerBank ID 205830427c1).
All assays were performed using the SYBR® Green method (Life
Technologies) on a ViiA™ 7 Real Time PCR System (Life Technologies). GAPDH (PrimerBank ID 126012538c1) was used as a reference
gene. Utrophin RNA quantiﬁcation was performed with the
Mm01168866_m1 TaqMan Gene Expression Assay (Life Technologies) multiplexed with GAPDH. Fold changes in expression were
calculated by using the average ΔΔCt for the gene of interest in
the control B10 group as the reference. Statistical analysis consisted of a two-way ANOVA followed by a Tukey’s multicomparison test performed on the ΔΔCt values.

BrdU staining
For bromodeoxyuridine (BrdU) labeling, the BrdU compound was
dissolved in the animal’s drinking water (0.8 mg/ml) when the
animals were 5 weeks of age. BrdU supplemented water was
given for 3 days. Labeled animals were sacriﬁced 4 days after removal of BrdU water. Frozen muscle tissues were mounted in Optimal Cutting Temperature compound (Tissue-Tek) and cut on a
microtome to produce 8 mm-thick cross sections. For BrdU antibody staining in muscle tissues, sections were ﬁrst allowed to air
dry for 5 min before being ﬁxed with HCl. The ﬁxation procedure
involved washing slides in Tris-buffered saline + 0.1% Tween-20
(TBST), then submerging them in acetone ( pre-chilled to −20°C)
for 10 min, followed by a second wash in TBST for 5 min. Fixed
slides were then incubated in 2N HCl for 1 h at 37°C, followed
by neutralization with 0.15 m sodium borate ( pH 8.5) for 10 min
at room temperature. Next, slides were washed with TBST and
then incubated in blocking buffer (2% BSA, 5% normal goat
serum, 0.5% Triton X-100 and 0.1% Tween-20 in PBS) for 1 h
at room temperature. Antibody buffer was made by diluting
the blocking buffer 1:10 with PBS. Blocked slides were washed
in PBS, then incubated with primary biotinylated anti-BrdU
antibody [(#B35138, Life Technologies) diluted 1:125 in antibody
buffer] and primary anti-laminin [(#L9393, Sigma–Aldrich)
diluted 1:125 in antibody buffer] overnight at 4°C. Slides were
then washed in PBS before incubation with streptavidin-FITC
secondary antibody [(#434311, Life Technologies) diluted 1:600 in
antibody buffer] and anti-rabbit Alexaﬂuor-594 [(#A11012, Life
Technologies) diluted 1:600 in antibody buffer] for 1 h at room temperature. Images were captured using an Olympus BX61 microscope with attached Olympus DP71 camera module. Counting
was performed in a blinded fashion using whole cross sections
of the TA muscle, with three whole cross sections per group.

Evan blue dye uptake
Evan blue dye (EBD) uptake by the gastrocnemius was quantiﬁed
as described previously (32) with minor modiﬁcations. EBD

Fiber size measurement and nuclear counting
After dissection, the hindlimbs were ﬁxed in 2% paraformaldehyde in PBS overnight at 4°C. The TA was then dissected and parafﬁn-embedded. Five-micron-thick microtome cross sections
were cut at the level of the belly of the muscle and stained for reticulin. The Gordon & Sweet’s Staining Protocol for Reticulin (33)
labels collagen III ﬁbrils in the extracellular matrix of the skeletal
muscle, allowing the delineation of individual muscle ﬁbers and
the measurement of their size on muscle cross sections. Slides
were deparafﬁnized and hydrated, oxidized in 1% potassium permanganate, bleached in 1% oxalic acid, sensitized in 2.5% ferric
ammonium sulfate, impregnated with freshly prepared working
silver solution (10% silver nitrate, sodium hydroxide and ammonium hydroxide), toned in 0.2% gold chloride solution, placed in
5% sodium thiosulfate, dehydrated, cleared and mounted. Slides
were scanned at a ×20 magniﬁcation on a digital slide scanner
(NanoZoomer 2.0HT, Hamamatsu). A region of interest was
drawn on the ventral side of the muscle and analyzed with ImageJ, using the Threshold and Analyze Particle functions, to return
the number of ﬁbers and their individual cross sectional areas.
An average of 400 ﬁbers were measured per muscle. Fiber size repartition was drawn using a 50-pixel binning. The percentage of
ﬁbers with centrally located nuclei was counted manually on the
same regions of interest. Fiber numbers were averaged and
ranked and plotted as a cumulative rank frequency and signiﬁcance was tested using the Kolmogorov–Smirnov (K–S) two sample test.

Myoﬁber isolation, phalloidin staining and
F-actin/myonuclear quantiﬁcation
Single myoﬁbers were isolated at 12 weeks ± 1 week from DBA/2
and DBA/2-mdx mice as previously described (20). Extensor digitorum longus muscles were dissected immediately after euthanasia and incubated in 0.2% Collagenase Type 1 (Sigma–Aldrich) in
DMEM for 1.5 h at 37°C, to digest the connective tissue. Single
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were performed by an operator who was blinded as to the genotype of the mouse: morphometry, CK, EBD uptake, central nuclei
and grip-strength measurements, and real-time PCR. Where appropriate, statistical signiﬁcance was calculated using either Student’s t-test or two-way ANOVA tests for independent samples
with post hoc Bonferroni comparisons for each possible pair of
groups, unless otherwise noted. Calculations were performed
using Prism v5 software (GraphPad Software). Any signiﬁcant differences (P < 0.05) between the two control strains are denoted
with the hash symbol. Signiﬁcant differences (P < 0.05) between
the C57BL/10 and the B10-mdx strains are denoted with a black
asterisk symbol. Any signiﬁcant differences (P < 0.05) between
the DBA/2 and D2-mdx strains are denoted with a gray asterisk
symbol (symbol colors correspond to the coat colors for the two
background strains).

Inﬂammatory marker detection

K.N. is supported by National Institutes of Health (5U54HD053177;
K26OD011171, P50AR060836-01), Muscular Dystrophy Association,
and US Department of Defense (W81XWH-05-1-0616, W81XWH11-1-0782). G.A.C., K.N. and C.L. are supported by US Department
of Defense (W81XWH-11-1-0330).

Jackson laboratory RT–QPCR
Total RNAs were extracted from the TA muscle using the Trizol
method, and 800 ng of total RNAs were treated with DNAse and
reverse-transcribed, with 40 ng of cDNA used per 10-µl quantitative PCR reaction. For the Jackson Laboratory inﬂammation
marker panel, the following assays were selected from the PrimerBank website [(Spandidos et al.), http://pga.mgh.harvard.edu/
primerbank/]: TNF-alpha (PrimerBank ID 133892368c1), interleukin-6 (PrimerBank ID 13624310c1), Mpeg1 (PrimerBank ID
133506752c1), Lgals3 (PrimerBank ID 225543162c1), CD53 (PrimerBank ID 161484612c1), CD48 (PrimerBank ID 145966847c1), Lyc6c1
(PrimerBank ID 26353880a1), LTB (PrimerBank ID 161760676c1)
and CD11b (PrimerBank ID 132626288c1).
For the CNMC inﬂammation panel, the following assays were selected from the Life Tech Taqman repository: HPRT1 (Taqman
Mm01545399_m1), B2M (Taqman Mm00437762_m1), CD247 (Taqman Mm00446171_m1), EMR1 (Taqman Mm00802529_m1), ICAM-1
(Taqman Mm00516023_m1), IFN-β1 (Taqman Mm00439552_s1), IL12α (Taqman Mm00434165_m1), IL15 (Taqman Mm00434210_m1),
IL1β (Taqman Mm00434228_m1), IL6 (Taqman Mm00446190_m1),
CCL2 (Taqman Mm00441242_m1), TNFα (Taqman Mm00443258_
m1), Ms4a1 (Taqman Mm00545909_m1) and VCAM (Taqman
Mm01320970_m1). The fold changes in expression were calculated
by using the average ΔΔCt for the gene of interest in the C57BL/10
group as reference. Statistical analysis consisted of a two-way
ANOVA followed by a Tukey’s multicomparison test performed on
the ΔΔCt values.

Statistical analysis
For the following experiments performed at the Jackson Laboratory, mouse handling and testing, tissue collection and analyses

Supplementary Material
Supplementary Material is available at HMG online.
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